Cargando…

Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients

INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohe, Yuka, Fushida, Sachio, Yamaguchi, Takahisa, Kinoshita, Jun, Saito, Hiroto, Okamoto, Koichi, Nakamura, Keishi, Tajima, Hidehiro, Ninomiya, Itasu, Ohta, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039245/
https://www.ncbi.nlm.nih.gov/pubmed/32110104
http://dx.doi.org/10.2147/CMAR.S241069
_version_ 1783500788572618752
author Ohe, Yuka
Fushida, Sachio
Yamaguchi, Takahisa
Kinoshita, Jun
Saito, Hiroto
Okamoto, Koichi
Nakamura, Keishi
Tajima, Hidehiro
Ninomiya, Itasu
Ohta, Tetsuo
author_facet Ohe, Yuka
Fushida, Sachio
Yamaguchi, Takahisa
Kinoshita, Jun
Saito, Hiroto
Okamoto, Koichi
Nakamura, Keishi
Tajima, Hidehiro
Ninomiya, Itasu
Ohta, Tetsuo
author_sort Ohe, Yuka
collection PubMed
description INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of malignancies. The peripheral blood neutrophil–lymphocyte ratio (NLR) has also been reported as a useful inflammation/immune indicator. However, there are few studies evaluating the relationship between these peripheral blood indicators and the effectiveness of chemotherapy. Thus, we examined these relationships in gastric cancer patients. PATIENTS AND METHODS: Between 2005 and 2018, 41 gastric cancer patients treated with preoperative DCS therapy (docetaxel, cisplatin, and S-1) therapy followed by gastrectomy were evaluated. Data for peripheral blood tests prior to the initiation of chemotherapy were used. The effectiveness of chemotherapy was determined using Response Evaluation Criteria in Solid Tumors (RECIST) and the pathological response of primary lesions (Ef grade). The relationship between the blood test results and the effectiveness of chemotherapy was evaluated. RESULTS: Each optimal cut-off value of peripheral inflammation/immune indicators was calculated through ROC curves. Although the pathological responder (Ef grade 2 or 3) revealed significantly better prognosis than the non-responder (Ef grade 0-1b), no relationship was found between responder according to RECIST and prognosis (P=0.014, P=0.992). In univariate analysis, a low PLR (<180, P=0.005), low NLR (<2.6, P=0.019), high lymphocyte (≥1.43, P=0.019) and high PNI (≥40, P=0.032) were identified as prognostic markers, whereas PLR was the only marker correlated with pathological response (P=0.031). CONCLUSION: PLR obtained prior to chemotherapy might be a useful indicator for predicting chemosensitivity owing to the simplicity of its procedure.
format Online
Article
Text
id pubmed-7039245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70392452020-02-27 Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients Ohe, Yuka Fushida, Sachio Yamaguchi, Takahisa Kinoshita, Jun Saito, Hiroto Okamoto, Koichi Nakamura, Keishi Tajima, Hidehiro Ninomiya, Itasu Ohta, Tetsuo Cancer Manag Res Original Research INTRODUCTION: Platelets are one factor promoting tumor development. Conversely, lymphocytes are one factor for immune protection. The peripheral blood platelets–lymphocyte ratio (PLR) is useful as an inflammation/immune indicator to predict postoperative recurrence and prognosis of a variety of malignancies. The peripheral blood neutrophil–lymphocyte ratio (NLR) has also been reported as a useful inflammation/immune indicator. However, there are few studies evaluating the relationship between these peripheral blood indicators and the effectiveness of chemotherapy. Thus, we examined these relationships in gastric cancer patients. PATIENTS AND METHODS: Between 2005 and 2018, 41 gastric cancer patients treated with preoperative DCS therapy (docetaxel, cisplatin, and S-1) therapy followed by gastrectomy were evaluated. Data for peripheral blood tests prior to the initiation of chemotherapy were used. The effectiveness of chemotherapy was determined using Response Evaluation Criteria in Solid Tumors (RECIST) and the pathological response of primary lesions (Ef grade). The relationship between the blood test results and the effectiveness of chemotherapy was evaluated. RESULTS: Each optimal cut-off value of peripheral inflammation/immune indicators was calculated through ROC curves. Although the pathological responder (Ef grade 2 or 3) revealed significantly better prognosis than the non-responder (Ef grade 0-1b), no relationship was found between responder according to RECIST and prognosis (P=0.014, P=0.992). In univariate analysis, a low PLR (<180, P=0.005), low NLR (<2.6, P=0.019), high lymphocyte (≥1.43, P=0.019) and high PNI (≥40, P=0.032) were identified as prognostic markers, whereas PLR was the only marker correlated with pathological response (P=0.031). CONCLUSION: PLR obtained prior to chemotherapy might be a useful indicator for predicting chemosensitivity owing to the simplicity of its procedure. Dove 2020-02-20 /pmc/articles/PMC7039245/ /pubmed/32110104 http://dx.doi.org/10.2147/CMAR.S241069 Text en © 2020 Ohe et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ohe, Yuka
Fushida, Sachio
Yamaguchi, Takahisa
Kinoshita, Jun
Saito, Hiroto
Okamoto, Koichi
Nakamura, Keishi
Tajima, Hidehiro
Ninomiya, Itasu
Ohta, Tetsuo
Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title_full Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title_fullStr Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title_full_unstemmed Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title_short Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients
title_sort peripheral blood platelet–lymphocyte ratio is good predictor of chemosensitivity and prognosis in gastric cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039245/
https://www.ncbi.nlm.nih.gov/pubmed/32110104
http://dx.doi.org/10.2147/CMAR.S241069
work_keys_str_mv AT oheyuka peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT fushidasachio peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT yamaguchitakahisa peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT kinoshitajun peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT saitohiroto peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT okamotokoichi peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT nakamurakeishi peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT tajimahidehiro peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT ninomiyaitasu peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients
AT ohtatetsuo peripheralbloodplateletlymphocyteratioisgoodpredictorofchemosensitivityandprognosisingastriccancerpatients